[1]
|
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B.B., Stein, C., Basit, A., Chan, J.C.N., Mbanya, J.C., Pavkov, M.E., Ramachandaran, A., Wild, S.H., James, S., Herman, W.H., Zhang, P., Bommer, C., Kuo, S., Boyko, E.J. and Magliano, D.J. (2022) IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prevalence Estimates for 2021 and Projections for 2045. Diabetes Research and Clinical Practice, 183, Article ID: 109119.
https://doi.org/10.1016/j.diabres.2021.109119
|
[2]
|
Forbes, J.M. and Fotheringham, A.K. (2017) Vascular Com-plications in Diabetes: Old Messages, New Thoughts. Diabetologia, 60, 2129-2138. https://doi.org/10.1007/s00125-017-4360-x
|
[3]
|
Forbes, J.M. and Cooper, M.E. (2013) Mechanisms of Diabetic Complications. Physiological Reviews, 93, 137-188.
https://doi.org/10.1152/physrev.00045.2011
|
[4]
|
Umanath, K. and Lewis, J.B. (2018) Update on Diabetic Nephropathy: Core Curriculum 2018. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 71, 884-895.
https://doi.org/10.1053/j.ajkd.2017.10.026
|
[5]
|
Yang, C., Wang, H., Zhao, X., Matsushita, K., Coresh, J., Zhang, L. and Zhao, M.H. (2020) CKD in China: Evolving Spectrum and Public Health Implications. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 76, 258-264. https://doi.org/10.1053/j.ajkd.2019.05.032
|
[6]
|
Koye, D.N., Shaw, J.E., Reid, C.M., Atkins, R.C., Reutens, A.T. and Magliano, D.J. (2017) Incidence of Chronic Kidney Disease among People with Diabetes: A Systematic Review of Observational Studies. Diabetic Medicine: A Journal of the British Diabetic Association, 34, 887-901. https://doi.org/10.1111/dme.13324
|
[7]
|
Rodriguez, F., Lee, D.J., Gad, S.S., Santos, M.P., Beetel, R.J., Vasey, J., Bailey, R.A., Patel, A., Blais, J., Weir, M.R. and Dash, R. (2021) Real-World Diagnosis and Treatment of Diabetic Kid-ney Disease. Advances in Therapy, 38, 4425-4441.
https://doi.org/10.1007/s12325-021-01777-9
|
[8]
|
McGrath, K. and Edi, R. (2019) Diabetic Kidney Disease: Diag-nosis, Treatment, and Prevention. American Family Physician, 99, 751-759.
|
[9]
|
Afkarian, M., Zelnick, L.R., Hall, Y.N., Heagerty, P.J., Tuttle, K., Weiss, N.S. and de Boer, I.H. (2016) Clinical Manifestations of Kidney Disease among US Adults with Diabetes, 1988-2014. JAMA, 316, 602-610.
https://doi.org/10.1001/jama.2016.10924
|
[10]
|
Yamanouchi, M., Furuichi, K., Hoshino, J., Ubara, Y. and Wada, T. (2020) Nonproteinuric Diabetic Kidney Disease. Clinical and Experimental Nephrology, 24, 573-581. https://doi.org/10.1007/s10157-020-01881-0
|
[11]
|
中华医学会糖尿病学分会微血管并发症学组. 中国糖尿病肾脏病防治指南(2021年版) [J]. 中华糖尿病杂志, 2021, 13(8): 762-784.
|
[12]
|
Barr, E.L.M., Barzi, F., Hughes, J.T., Jerums, G., Hoy, W.E., O’Dea, K., Jones, G.R.D., Lawton, P.D., Brown, A.D.H., Thomas, M., Ekinci, E.I., Sinha, A., Cass, A., MacIsaac, R.J. and Maple-Brown, L.J. (2018) High Baseline Levels of Tumor Necrosis Factor Receptor 1 Are Associated with Progression of Kidney Disease in Indigenous Australians with Diabetes: The eGFR Follow-up Study. Diabetes Care, 41, 739-747. https://doi.org/10.2337/dc17-1919
|
[13]
|
Pavkov, M.E., Weil, E.J., Fufaa, G.D., Nel-son, R.G., Lemley, K.V., Knowler, W.C., Niewczas, M.A. and Krolewski, A.S. (2016) Tumor Necrosis Factor Recep-tors 1 and 2 Are Associated with Early Glomerular Lesions in Type 2 Diabetes. Kidney International, 89, 226-234. https://doi.org/10.1038/ki.2015.278
|
[14]
|
Chauhan, K., Verghese, D.A., Rao, V., Chan, L., Parikh, C.R., Coca, S.G. and Nadkarni, G.N. (2019) Plasma Endostatin Predicts Kidney Outcomes in Patients with Type 2 Diabetes. Kidney In-ternational, 95, 439-446.
https://doi.org/10.1016/j.kint.2018.09.019
|
[15]
|
Mori, Y., Ajay, A.K., Chang, J.H., Mou, S., Zhao, H., Kishi, S., Li, J., Brooks, C.R., Xiao, S., Woo, H.M., Sabbisetti, V.S., Palmer, S.C., Galichon, P., Li, L., Henderson, J.M., Kuchroo, V.K., Hawkins, J., Ichimura, T. and Bonventre, J.V. (2021) KIM-1 Mediates Fatty Acid Uptake by Renal Tubular Cells to Promote Progressive Diabetic Kidney Disease. Cell Metabolism, 33, 1042-1061.e7. https://doi.org/10.1016/j.cmet.2021.04.004
|
[16]
|
Mogensen, C.E., Christensen, C.K. and Vittinghus, E. (1983) The Stages in Diabetic Renal Disease: With Emphasis on the Stage of Incipient Diabetic Nephropathy. Diabetes, 32, 64-78. https://doi.org/10.2337/diab.32.2.S64
|
[17]
|
Biesenbach, G., Bodlaj, G., Pieringer, H. and Sedlak, M. (2011) Clinical versus Histological Diagnosis of Diabetic Nephropathy—Is Renal Biopsy Required in Type 2 Diabetic Patients with Re-nal Disease? QJM: An International Journal of Medicine, 104, 771-774. https://doi.org/10.1093/qjmed/hcr059
|
[18]
|
中华医学会肾脏病学分会专家组. 糖尿病肾脏疾病临床诊疗中国指南[J]. 中华肾脏病杂志, 2021, 37(3): 255-304.
|
[19]
|
ElSayed, N.A., Aleppo, G., Aroda, V.R., Bannuru, R.R., Brown, F.M., Bruemmer, D., Collins, B.S., Cusi, K., Das, S.R., Gibbons, C.H., Giurini, J.M., Hilliard, M.E., Isaacs, D., Johnson, E.L., Kahan, S., Khunti, K., Kosiborod, M., Leon, S.K. Lyons, L. Murdock, M.L. Perry, P. Prahalad, R.E. Pratley, J.J. Seley, R.C. Stanton, J.K. Sun, C.C. Woodward, J., Young-Hyman, D., Gabbay, R.A. and on Behalf of the American Diabetes Association. (2023) In-troduction and Methodology: Standards of Care in Diabetes—2023. Diabetes Care, 46, S1-S4. https://doi.org/10.2337/dc23-Sint
|
[20]
|
Improving Global Outcomes (KDIGO) Diabetes Work Group (2022) KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 102, S1-S127.
https://doi.org/10.1016/j.kint.2022.06.008
|
[21]
|
Hostetter, T.H., Meyer, T.W., Rennke, H.G. and Brenner, B.M. (1986) Chronic Effects of Dietary Protein in the Rat with Intact and Reduced Renal Mass. Kidney International, 30, 509-517. https://doi.org/10.1038/ki.1986.215
|
[22]
|
Chen, Y., Wang, X., Jia, Y., Zou, M., Zhen, Z. and Xue, Y. (2022) Effect of a Sodium Restriction Diet on Albuminuria and Blood Pressure in Diabetic Kidney Disease Patients: A Meta-Analysis. International Urology and Nephrology, 54, 1249-1260. https://doi.org/10.1007/s11255-021-03035-x
|
[23]
|
Giacchetti, G., Sechi, L.A., Rilli, S. and Carey, R.M. (2005) The Renin-Angiotensin-Aldosterone System, Glucose Metabolism and Diabetes. Trends in Endocrinology and Metabolism, 16, 120-126.
https://doi.org/10.1016/j.tem.2005.02.003
|
[24]
|
Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B., Ritz, E., Atkins, R.C., Rohde, R. and Raz, I. (2001) Renoprotective Effect of the Angiotensin-Receptor An-tagonist Irbesartan in Patients with Nephropathy due to Type 2 Diabetes. The New England Journal of Medicine, 345, 851-860. https://doi.org/10.1056/NEJMoa011303
|
[25]
|
Donate-Correa, J., Luis-Rodríguez, D., Martín-Núñez, E., Tagua, V.G., Hernández-Carballo, C., Ferri, C., Rodríguez- Rodríguez, A.E., Mora-Fernández, C. and Navarro-González, J.F. (2020) Inflammatory Targets in Diabetic Nephropathy. Journal of Clinical Medicine, 9, Article 458. https://doi.org/10.3390/jcm9020458
|
[26]
|
Thallas-Bonke, V., Thorpe, S.R., Coughlan, M.T., Fukami, K., Yap, F.Y., Sourris, K.C., Penfold, S.A., Bach, L.A., Cooper, M.E. and Forbes, J.M. (2008) Inhibition of NADPH Oxidase Pre-vents Advanced Glycation End Product— Mediated Damage in Diabetic Nephropathy through a Protein Kinase C-α-Dependent Pathway. Diabetes, 57, 460-469.
https://doi.org/10.2337/db07-1119
|
[27]
|
Fioretto, P., Zambon, A., Rossato, M., Busetto, L. and Vettor, R. (2016) SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care, 39, S165-S171. https://doi.org/10.2337/dcS15-3006
|
[28]
|
Dia, B., Alkhansa, S., Njeim, R., Al Moussawi, S., Farhat, T., Haddad, A., Riachi, M.E., Nawfal, R., Azar, W.S. and Eid, A.A. (2023) SGLT2 Inhibitor—Dapagliflozin Attenuates Diabe-tes-Induced Renal Injury by Regulating Inflammation through a CYP4A/20-HETE Signaling Mechanism. Pharmaceutics, 15, Article 965.
https://doi.org/10.3390/pharmaceutics15030965
|
[29]
|
Tomita, I., Kume, S., Sugahara, S., Osawa, N., Yamahara, K., Yasuda-Yamahara, M., Takeda, N., Chin-Kanasaki, M., Kaneko, T., Mayoux, E., Mark, M., Yanagita, M., Ogita, H., Araki, S.I. and Maegawa, H. (2020) SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition. Cell Metabolism, 32, 404-419.E6. https://doi.org/10.1016/j.cmet.2020.06.020
|
[30]
|
Jongs, N., Greene, T., Chertow, G.M., McMurray, J.J.V., Lang-kilde, A.M., Correa-Rotter, R., Rossing, P., Sjöström, C.D., Stefansson, B.V., Toto, R.D., Wheeler, D.C. and Heerspink, H.J.L. (2021) Effect of Dapagliflozin on Urinary Albumin Excretion in Patients with Chronic Kidney Disease with and without Type 2 Diabetes: A Prespecified Analysis from the DAPA-CKD Trial. The Lancet Diabetes & Endocrinology, 9, 755-766.
https://doi.org/10.1016/S2213-8587(21)00243-6
|
[31]
|
Barrera-Chimal, J., Lima-Posada, I., Bakris, G.L. and Jaisser, F. (2022) Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease—Mechanistic and Therapeutic Effects. Nature Reviews Nephrology, 18, 56-70.
https://doi.org/10.1038/s41581-021-00490-8
|
[32]
|
Frampton, J.E. (2021) Finerenone: First Approval. Drugs, 81, 1787-1794. https://doi.org/10.1007/s40265-021-01599-7
|
[33]
|
Bakris, G.L., Agarwal, R., Anker, S.D., Pitt, B., Ruilope, L.M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A. and Filippatos, G. (2020) Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 383, 2219-2229. https://doi.org/10.1056/NEJMoa2025845
|
[34]
|
Filippatos, G., Anker, S.D., Agarwal, R., Ruilope, L.M., Rossing, P., Bakris, G.L., Tasto, C., Joseph, A., Kolkhof, P., Lage, A. and Pitt, B. (2022) Finerenone Reduces Risk of Incident Heart Failure in Patients with Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial. Circulation, 145, 437-447.
https://doi.org/10.1161/CIRCULATIONAHA.121.057983
|
[35]
|
李金菊, 刘旺华, 李花, 李甜, 夏琳, 何翔. 糖尿病肾病不同证型舌象的客观化研究[J]. 亚太传统医药, 2021, 17(4): 161-165.
|
[36]
|
郑依玲, 梅全喜, 李文佳, 唐志芳, 钱正明, 陶盛昌, 董鹏鹏. 冬虫夏草的药用历史及现代服用方法探讨[J]. 中药材, 2017, 40(11): 2722-2725.
|
[37]
|
陈仁慈, 项洁琼, 陈洪宇. 冬虫夏草治疗糖尿病肾病疗效的系统评价[J]. 中国中西医结合肾病杂志, 2017, 18(4): 340-344.
|
[38]
|
Wang, C., Hou, X.X., Rui, H.L., Li, L.J., Zhao, J., Yang, M., Sun, L.J., Dong, H.R., Cheng, H. and Chen, Y.P. (2018) Artificially Cultivated Ophiocordyceps sinensis Alleviates Diabetic Nephropathy and Its Podocyte Injury via Inhibiting P2X7R Expression and NLRP3 Inflammasome Activation. Journal of Diabetes Re-search, 2018, Article ID: 1390418.
https://doi.org/10.1155/2018/1390418
|
[39]
|
徐喆, 赵凯, 李志军. 冬虫夏草对糖尿病肾病大鼠肾小管细胞中AMPK/mTOR信号传导途径的影响[J]. 中国现代医学杂志, 2018, 28(3): 1-5.
|
[40]
|
Wu, W.T., Hsu, T.H., Lee, C.H. and Lo, H.C. (2020) Fruiting Bodies of Chinese Caterpillar Mushroom, Ophiocordyceps sinensis (Ascomycetes) Allevi-ate Diabetes-Associated Oxidative Stress. International Journal of Medicinal Mushrooms, 22, 15-29. https://doi.org/10.1615/IntJMedMushrooms.2019033275
|
[41]
|
中国医师协会中西医结合医师分会内分泌与代谢病学专业委员会. 糖尿病肾病病证结合诊疗指南[J]. 中医杂志, 2022, 63(2): 190-197.
|